Highlights

• Elevra Lithium delivered FY26 revenue of US$202 million, up 39%, while underlying Group EBITDA swung to a US$14 million profit from a US$43 million loss in FY25.
• North American Lithium produced 197,967 dmt of spodumene concentrate, while the average realised selling price climbed 57% to US$1,092/dmt.
• The company finished FY26 with US$255 million in cash, while its fully funded NAL Brownfield Expansion is expected to lift Stage 1 annual production capacity by 15–20%.

FY26 Turnaround Draws Attention to ELV SharesElevra Lithium Limited (ASX: ELV) attracted market attention following the release of its FY26 results, with the stock trading at a current market price (CMP) of AU$8.550, surging 2.02%. The result marked Elevra’s first full financial year as the combined business created through the merger of Sayona Mining and Piedmont Lithium, with stronger lithium pricing, operating improvements and fresh growth funding reshaping the company’s financial position.For the year ended 30 June 2026, revenue advanced 39% to US$202 million, compared with US$145 million in FY25. Underlying Group EBITDA improved by US$57 million, reaching a positive US$14 million versus a US$43 million loss a year earlier. Profit after income tax reached approximately US$44 million, reversing the prior-year loss of US$247 million.Higher Lithium Pricing Changes the Earnings EquationThe biggest financial driver was price realisation. Elevra achieved an average realised spodumene selling price of US$1,092/dmt FOB, representing a 57% increase from US$694/dmt in FY25. The improvement in pricing was strong enough to offset the impact of lower spodumene concentrate sales volumes.Unit operating cost per tonne sold increased only 2% to US$853/dmt, from US$835/dmt. Importantly, realised pricing moved comfortably above unit operating cost, producing an implied operating spread of roughly US$239/dmt before other corporate and accounting items. This represents a meaningful improvement in NAL's unit economics as lithium pricing strengthened and legacy commercial arrangements were progressively restructured.NAL Operations Finish FY26 on Stronger FootingAt the North American Lithium mine, ore mined reached a record 1.47 million wet metric tonnes, an increase of 14%, while approximately 1.40 million dmt of ore was processed. Spodumene concentrate production came in at 197,967 dmt, down 3%, with sales declining 13% to 181,494 dmt.The weaker annual production comparison largely reflected temporary first-half mining constraints and lower-quality ore feed. However, operational momentum improved late in the year. Lithium recovery reached 71% in the June quarter, while quarterly production rose to 54,479 dmt. May also delivered a monthly production record of 22,202 dmt. Full-year mill utilisation remained robust at 91%.Cash Position Provides Growth FlexibilityElevra closed FY26 with US$255 million in cash, substantially higher than US$47 million at the end of FY25. Net assets stood at approximately US$727 million. The stronger liquidity position followed capital raisings, cash acquired through the Piedmont merger and funding secured for expansion activities.The company also reported US$15 million of merger-related cost synergies during the ten months of combined operations. These savings were primarily generated through lower corporate and administrative expenditure, helping the enlarged business move towards a more efficient cost structure.NAL Expansion Could Lift the Production ProfileThe next major catalyst is the staged NAL Brownfield Expansion. Stage 1 is expected to increase annual production capacity by approximately 15–20% from mid-CY27. The broader staged expansion carries an incremental post-tax NPV8 of CA$969 million, equivalent to approximately US$718 million.NAL's Mineral Resource has increased to 95.0 million tonnes at 1.15% Li₂O, while Ore Reserves reached 48.6 million tonnes at 1.11% Li₂O. The larger reserve base provides greater support for a longer-duration production strategy and the proposed capacity expansion.Moblan Adds Another Long-Term Growth OptionElevra's 60%-owned Moblan Lithium Project also strengthened materially. Its Mineral Resource increased 30% to 121.0 million tonnes at 1.19% Li₂O, while Ore Reserves expanded 39% to 48.1 million tonnes at 1.31% Li₂O.Funding has been allocated toward permitting, environmental activities and an updated Definitive Feasibility Study, positioning Moblan for progression toward a future Final Investment Decision.What Does FY27 Guidance Signal?For FY27, Elevra expects spodumene concentrate production of 198,000–210,000 dmt, alongside sales volumes of 200,000–230,000 dmt. Unit operating cost guidance is US$880–US$950/dmt sold, while capital expenditure is expected at US$120–US$140 million.The higher cost range reflects inflation, currency translation, a planned 10:1 strip ratio and pre-strip expenditure associated with Phase 4 ahead of the NAL expansion.Can ELV Sustain the Momentum?From an equity-research perspective, Elevra enters FY27 from a considerably stronger position than a year earlier. Pricing has recovered, NAL is generating positive underlying EBITDA, liquidity has expanded materially and the principal brownfield growth project is fully funded.The key question for investors now shifts from financial recovery to execution. Delivery of the NAL expansion, maintaining recovery rates, managing the expected rise in unit costs and successfully converting higher lithium prices into cash generation will be central to the next phase. With ELV at AU$8.550 after a 2.02% rise, further momentum is likely to depend on whether Elevra can translate its enlarged resource base and stronger balance sheet into sustainable production growth and improving operating margins through FY27.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au